# A Study of Galcanezumab in Participants With Chronic Cluster Headache

> **NCT02438826** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 240 (actual)

## Conditions studied

- Chronic Cluster Headache

## Interventions

- **DRUG:** Galcanezumab 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02438826
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-18
- **Primary completion:** 2018-03-27
- **Final completion:** 2019-08-14
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02438826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02438826, "A Study of Galcanezumab in Participants With Chronic Cluster Headache". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02438826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*